COVID-19 nasal vaccine candidate effective at preventing disease transmission
The Pharma Data
SEPTEMBER 30, 2021
. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.
Let's personalize your content